Caribou Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRBU research report →
About the company
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally.
- CEO
- Rachel E. Haurwitz
- IPO
- 2021
- Employees
- 147
- HQ
- Berkeley, CA, US
Price Chart
- Market Cap
- $180.51M
- P/E
- -1.28
- P/S
- 16.11
- P/B
- 1.71
- EV/EBITDA
- -1.75
- Div Yield
- 0.00%
- Gross Margin
- 82.62%
- Op Margin
- -1175.68%
- Net Margin
- -1189.14%
- ROE
- -100.13%
- ROIC
- -100.43%
- Revenue
- $11.16M · 11.66%
- Net Income
- $-148,125,000 · 0.66%
- EPS
- $-1.59 · 3.64%
- Op Income
- $-136,194,000
- FCF YoY
- 22.36%
- 52W High
- $3.54
- 52W Low
- $1.33
- 50D MA
- $1.95
- 200D MA
- $1.93
- Beta
- 2.37
- Avg Volume
- 1.91M
Get TickerSpark's AI analysis on CRBU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 25, 26 | Kelly Timothy P | sell | 6,228 |
| Feb 20, 26 | Kelly Timothy P | other | 202,500 |
| Feb 20, 26 | Kelly Timothy P | other | 45,000 |
| Feb 24, 26 | Kelly Timothy P | sell | 3,147 |
| Feb 20, 26 | MCCLUNG BARBARA G | other | 45,000 |
| Feb 24, 26 | MCCLUNG BARBARA G | sell | 6,938 |
| Feb 20, 26 | MCCLUNG BARBARA G | other | 202,500 |
| Feb 20, 26 | Khan Ruhi Ahmad | other | 202,500 |
| Feb 20, 26 | Khan Ruhi Ahmad | other | 45,000 |
| Feb 24, 26 | Khan Ruhi Ahmad | sell | 6,938 |
Our CRBU coverage
Recent articles, reports, and earnings notes.
No research on CRBU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRBU report →Similar companies
Peers in the same neighborhood.